xCantor Fitzgerald Downgrades Bristol-Myers Squibb to Neutral, Lowers Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has downgraded Bristol-Myers Squibb (BMY) from Overweight to Neutral and reduced the price target from $68 to $55.
November 15, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bristol-Myers Squibb was downgraded by Cantor Fitzgerald from Overweight to Neutral, with a price target cut from $68 to $55.
Downgrades by analysts can lead to a negative perception among investors, potentially causing a short-term decline in the stock price. The reduction in the price target further suggests a lower expected future performance, which may also contribute to a decrease in stock value.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100